Sushma Reddy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sushma Reddy has a total of 183 co-authors. Here are the top co-authors by number of shared publications:
Daniel Bernstein
Department of Pediatrics (Cardiology) Stanford University Palo Alto CA
7 shared publicationsMingming Zhao
Department of Pediatrics, Division of Cardiology, Stanford University School of Medicine, Stanford, CA 94305
7 shared publications- Daniel Bernstein
Department of Pediatrics, Stanford University School of Medicine, Stanford, USA
5 shared publications - Edda Spiekerkoetter
Stanford University
5 shared publications Giovanni Fajardo
Department of Pediatrics (S.Ranjbarvaziri, G.F., M.Z., A.S.V.R., S.Reddy, K.M.R., D.B.), Stanford University School of Medicine, CA
5 shared publicationsDong-Qing Hu
Affiliation Division of Cardiology, Department of Pediatrics, Stanford University, Stanford, California, United States of America
4 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (18)
Accelerated Aging Fontan Phenotype Is Associated With Systemic Right Ventricles and Adverse Hemodynamics
Background: Accelerated biological aging occurs when biological age outpaces chronological age. Congenital heart disease is associated with an increased risk for age‐related diseases. The role of biological aging in individuals with the most severe forms of congenital heart disease, those with a Fontan circulation, is not known. Methods: In this case–control study, we compared the telomere lengths of patients with Fontan circulation with controls and identified factors associated with an accelerated aging phenotype. Biological aging was assessed by leukocyte telomere length through quantitative polymerase chain reaction, expressed as telomeric DNA to single‐copy gene ratio. Results: Median age was 14.90 (interquartile range [IQR], 10.99–20.69) years in the Fontan cohort (N=90) and 15.20 (IQR, 11.11–16.42) years in controls (N=59). The Fontan cohort had shorter telomeres compared with controls (telomeric DNA to single‐copy gene ratio, 1.04 [IQR, 0.96–1.14] versus 1.13 [IQR, 0.96–1.24]; P =0.021). Patients with systemic right ventricles had shorter telomeres (telomeric DNA to single‐copy gene ratio, 1.02 [IQR, 0.93–1.08] versus 1.05 [IQR, 1.00–1.17]; P =0.047). Lower superior vena cava saturation (β=0.007 [95% CI, 0.002, 0.012]; P =0.013), lower cardiac index (β=0.06 [95% CI, 0.012–0.108]; P =0.016) and higher systemic vascular resistance (β=−0.007 [95% CI, −0.014 to −0.001]; P =0.023) were associated with shorter telomeres. At a median follow‐up of 13.07 months, 46.7% of patients with telomere loss (>50 bp loss/y) experienced an increase in comorbidities, compared with just 20.5% in those with no change or an increase in telomere length ( P <0.001). Conclusions: Individuals with a Fontan circulation have shorter telomeres compared with controls, mirroring an accelerated aging phenotype. This is more pronounced in patients with a systemic right ventricle, those with adverse hemodynamics, and is associated with having a higher burden of comorbidities. Understanding accelerated biological aging will allow for the development of therapies aimed at slowing age‐related decline.
- 15 September 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (18)
Open AccessAccelerated Aging Fontan Phenotype Is Associated With Systemic Right Ventricles and Adverse Hemodynamics
Background: Accelerated biological aging occurs when biological age outpaces chronological age. Congenital heart disease is associated with an increased risk for age‐related diseases. The role of biological aging in individuals with the most severe forms of congenital heart disease, those with a Fontan circulation, is not known. Methods: In this case–control study, we compared the telomere lengths of patients with Fontan circulation with controls and identified factors associated with an accelerated aging phenotype. Biological aging was assessed by leukocyte telomere length through quantitative polymerase chain reaction, expressed as telomeric DNA to single‐copy gene ratio. Results: Median age was 14.90 (interquartile range [IQR], 10.99–20.69) years in the Fontan cohort (N=90) and 15.20 (IQR, 11.11–16.42) years in controls (N=59). The Fontan cohort had shorter telomeres compared with controls (telomeric DNA to single‐copy gene ratio, 1.04 [IQR, 0.96–1.14] versus 1.13 [IQR, 0.96–1.24]; P =0.021). Patients with systemic right ventricles had shorter telomeres (telomeric DNA to single‐copy gene ratio, 1.02 [IQR, 0.93–1.08] versus 1.05 [IQR, 1.00–1.17]; P =0.047). Lower superior vena cava saturation (β=0.007 [95% CI, 0.002, 0.012]; P =0.013), lower cardiac index (β=0.06 [95% CI, 0.012–0.108]; P =0.016) and higher systemic vascular resistance (β=−0.007 [95% CI, −0.014 to −0.001]; P =0.023) were associated with shorter telomeres. At a median follow‐up of 13.07 months, 46.7% of patients with telomere loss (>50 bp loss/y) experienced an increase in comorbidities, compared with just 20.5% in those with no change or an increase in telomere length ( P <0.001). Conclusions: Individuals with a Fontan circulation have shorter telomeres compared with controls, mirroring an accelerated aging phenotype. This is more pronounced in patients with a systemic right ventricle, those with adverse hemodynamics, and is associated with having a higher burden of comorbidities. Understanding accelerated biological aging will allow for the development of therapies aimed at slowing age‐related decline.
- Open Access
β 2 -Adrenergic Signaling Switches from Cardioprotective to Cardiotoxic in Acute vs. Chronic Oxidative Stress
BACKGROUND AND PURPOSE: β-adrenergic receptors (AR) regulate both cardiac function and remodeling. Many studies suggest that, in addition to their effects on heart rate and contractility, β 1 -ARs mediate cardiotoxic signaling, whereas β 2 -ARs are generally cardioprotective. However, there is conflicting data on the role of β 2 -ARs, differing dependent on the nature of the stress. Given the extremely common use of β-blockers and agonists clinically, we sought to understand the differential cardioprotective/cardiotoxic effects of β 2 -AR signaling dependent on timing (acute vs. chronic) and type of cardiotoxic stress. EXPERIMENTAL APPROACH: Wild-type (WT) and β-AR knockout (β 1 -KO and β 2 -KO) mice were subjected to acute (15 mg·kg -1 x 1 dose) or chronic (2 mg·kg -1 ·wk -1 x 7 wks) oxidative stress using doxorubicin (DOX). Survival, cardiac function and histopathology were assessed and differential signaling activation determined by Western blot and gene expression by RNA-seq. KEY RESULTS: We have shown that β 2 -KOs manifest extreme cardiotoxicity with acute DOX (100% mortality within 30 min), supporting a strong cardioprotective role of β 2 -signaling. In marked contrast, with chronic DOX, β 2 -KO had enhanced survival (t½ 54 d vs. 42 d in WT) and attenuated cardiac dysfunction. In β 2 -KO, acute DOX activated stress MAPKs (p38, ERK and JNK), whereas chronic DOX did not; furthermore, in the absence of β2-ARs, oxidative stress and lipid accumulation were reduced, genes regulating compensatory metabolic pathways (AMPK and insulin/PI3K) were upregulated, and genes regulating mitochondrial and contractile function were preserved, whereas they were downregulated in WT with chronic DOX. CONCLUSIONS: β 2 -AR signaling switches from being cardioprotective during acute oxidative stress, to cardiotoxic during chronic stress. Inhibition of β 2 -AR signaling during chronic stress induces signaling and metabolic compensations that serve to reduce oxidative injury. This unexpected temporal switching has potential significant implications for all models of cardiovascular disease, as well as for the clinical use of subtype-specific β-blockers. CLINICAL PERSPECTIVE: What is new?: Our finding that β2-adrenergic receptor signaling can switch from being beneficial (cardioprotective) to detrimental (cardiotoxic) depending on the acuteness or chronicity of a cardiac stressor. Identification of the mechanisms by which this temporal switch is mediated could lead to new drug development. What are the clinical implications?: Our findings provide potential guidance in choosing between a β1-specific vs. a β1/2-non-specific drug when treating specific cardiovascular diseases based on their temporal characteristics. The temporal protective/toxic switching that we describe could be a mechanism common to many other drugs, yet is rarely tested, suggesting the need for additional studies using temporal course as a factor.
Open Accessβ 2 -Adrenergic Signaling Switches from Cardioprotective to Cardiotoxic in Acute vs. Chronic Oxidative Stress
BACKGROUND AND PURPOSE: β-adrenergic receptors (AR) regulate both cardiac function and remodeling. Many studies suggest that, in addition to their effects on heart rate and contractility, β 1 -ARs mediate cardiotoxic signaling, whereas β 2 -ARs are generally cardioprotective. However, there is conflicting data on the role of β 2 -ARs, differing dependent on the nature of the stress. Given the extremely common use of β-blockers and agonists clinically, we sought to understand the differential cardioprotective/cardiotoxic effects of β 2 -AR signaling dependent on timing (acute vs. chronic) and type of cardiotoxic stress. EXPERIMENTAL APPROACH: Wild-type (WT) and β-AR knockout (β 1 -KO and β 2 -KO) mice were subjected to acute (15 mg·kg -1 x 1 dose) or chronic (2 mg·kg -1 ·wk -1 x 7 wks) oxidative stress using doxorubicin (DOX). Survival, cardiac function and histopathology were assessed and differential signaling activation determined by Western blot and gene expression by RNA-seq. KEY RESULTS: We have shown that β 2 -KOs manifest extreme cardiotoxicity with acute DOX (100% mortality within 30 min), supporting a strong cardioprotective role of β 2 -signaling. In marked contrast, with chronic DOX, β 2 -KO had enhanced survival (t½ 54 d vs. 42 d in WT) and attenuated cardiac dysfunction. In β 2 -KO, acute DOX activated stress MAPKs (p38, ERK and JNK), whereas chronic DOX did not; furthermore, in the absence of β2-ARs, oxidative stress and lipid accumulation were reduced, genes regulating compensatory metabolic pathways (AMPK and insulin/PI3K) were upregulated, and genes regulating mitochondrial and contractile function were preserved, whereas they were downregulated in WT with chronic DOX. CONCLUSIONS: β 2 -AR signaling switches from being cardioprotective during acute oxidative stress, to cardiotoxic during chronic stress. Inhibition of β 2 -AR signaling during chronic stress induces signaling and metabolic compensations that serve to reduce oxidative injury. This unexpected temporal switching has potential significant implications for all models of cardiovascular disease, as well as for the clinical use of subtype-specific β-blockers. CLINICAL PERSPECTIVE: What is new?: Our finding that β2-adrenergic receptor signaling can switch from being beneficial (cardioprotective) to detrimental (cardiotoxic) depending on the acuteness or chronicity of a cardiac stressor. Identification of the mechanisms by which this temporal switch is mediated could lead to new drug development. What are the clinical implications?: Our findings provide potential guidance in choosing between a β1-specific vs. a β1/2-non-specific drug when treating specific cardiovascular diseases based on their temporal characteristics. The temporal protective/toxic switching that we describe could be a mechanism common to many other drugs, yet is rarely tested, suggesting the need for additional studies using temporal course as a factor.
- 1 August 2025
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 18 (8) , e013241
Response by Reddy to Letter Regarding Article, “Plasma Proteomics of the Fontan Circulation Reveal Signatures of Oxidative Stress and Cell Death”
- 1 August 2025
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 18 (8) , e013241
Response by Reddy to Letter Regarding Article, “Plasma Proteomics of the Fontan Circulation Reveal Signatures of Oxidative Stress and Cell Death”
- Open Access
- 1 May 2025
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 18 (5) , e012136
Plasma Proteomics of the Fontan Circulation Reveal Signatures of Oxidative Stress and Cell Death
BACKGROUND: Single ventricle congenital heart disease like hypoplastic left heart syndrome with a Fontan circulation constitutes, the largest group of children hospitalized with circulation failure, experiencing an in-hospital mortality rate of 20% to 50%. We investigated the mechanisms leading to Fontan failure to identify novel therapeutic targets. METHODS: Blood was collected from patients with hypoplastic left heart syndrome post-Fontan and controls (n=6/group). Plasma microvesicles were isolated, and proteomics assessed using data-independent acquisition mass spectroscopy. Dysregulated proteins with a fold change >1.5 or ≤1.5, P r =0.91), mitochondrial reactive oxygen species generation (HSPD1, r =0.81; ATP5F1A, r =0.75), and cytoskeletal proteins (ANK1, r =0.63; ACTN1, r =0.76). CONCLUSIONS: Proteins from circulating microvesicles from patients with hypoplastic left heart syndrome post-Fontan are mostly from the liver. While this pilot study is limited by its sample size and may not represent the broader Fontan population, the proteomic changes were associated with worsening heart failure and cyanosis, suggesting their potential utility as biomarkers.
- 1 May 2025
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 18 (5) , e012136
Open AccessPlasma Proteomics of the Fontan Circulation Reveal Signatures of Oxidative Stress and Cell Death
BACKGROUND: Single ventricle congenital heart disease like hypoplastic left heart syndrome with a Fontan circulation constitutes, the largest group of children hospitalized with circulation failure, experiencing an in-hospital mortality rate of 20% to 50%. We investigated the mechanisms leading to Fontan failure to identify novel therapeutic targets. METHODS: Blood was collected from patients with hypoplastic left heart syndrome post-Fontan and controls (n=6/group). Plasma microvesicles were isolated, and proteomics assessed using data-independent acquisition mass spectroscopy. Dysregulated proteins with a fold change >1.5 or ≤1.5, P r =0.91), mitochondrial reactive oxygen species generation (HSPD1, r =0.81; ATP5F1A, r =0.75), and cytoskeletal proteins (ANK1, r =0.63; ACTN1, r =0.76). CONCLUSIONS: Proteins from circulating microvesicles from patients with hypoplastic left heart syndrome post-Fontan are mostly from the liver. While this pilot study is limited by its sample size and may not represent the broader Fontan population, the proteomic changes were associated with worsening heart failure and cyanosis, suggesting their potential utility as biomarkers.
- 1 April 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 18 (4) , e017415
Abnormalities in Coronary Microvasculature in Pulmonary Atresia With Intact Ventricular Septum
- 1 April 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 18 (4) , e017415
Abnormalities in Coronary Microvasculature in Pulmonary Atresia With Intact Ventricular Septum
- 21 June 2024
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 135 (1) , 60-75
3D Imaging Reveals Complex Microvascular Remodeling in the Right Ventricle in Pulmonary Hypertension
BACKGROUND: Pathogenic concepts of right ventricular (RV) failure in pulmonary arterial hypertension focus on a critical loss of microvasculature. However, the methods underpinning prior studies did not take into account the 3-dimensional (3D) aspects of cardiac tissue, making accurate quantification difficult. We applied deep-tissue imaging to the pressure-overloaded RV to uncover the 3D properties of the microvascular network and determine whether deficient microvascular adaptation contributes to RV failure. METHODS: Heart sections measuring 250-µm-thick were obtained from mice after pulmonary artery banding (PAB) or debanding PAB surgery and properties of the RV microvascular network were assessed using 3D imaging and quantification. Human heart tissues harvested at the time of transplantation from pulmonary arterial hypertension cases were compared with tissues from control cases with normal RV function. RESULTS: Longitudinal 3D assessment of PAB mouse hearts uncovered complex microvascular remodeling characterized by tortuous, shorter, thicker, highly branched vessels, and overall preserved microvascular density. This remodeling process was reversible in debanding PAB mice in which the RV function recovers over time. The remodeled microvasculature tightly wrapped around the hypertrophied cardiomyocytes to maintain a stable contact surface to cardiomyocytes as an adaptation to RV pressure overload, even in end-stage RV failure. However, microvasculature-cardiomyocyte contact was impaired in areas with interstitial fibrosis where cardiomyocytes displayed signs of hypoxia. Similar to PAB animals, microvascular density in the RV was preserved in patients with end-stage pulmonary arterial hypertension, and microvascular architectural changes appeared to vary by etiology, with patients with pulmonary veno-occlusive disease displaying a lack of microvascular complexity with uniformly short segments. CONCLUSIONS: 3D deep tissue imaging of the failing RV in PAB mice, pulmonary hypertension rats, and patients with pulmonary arterial hypertension reveals complex microvascular changes to preserve the microvascular density and maintain a stable microvascular-cardiomyocyte contact. Our studies provide a novel framework to understand microvascular adaptation in the pressure-overloaded RV that focuses on cell-cell interaction and goes beyond the concept of capillary rarefaction.
- 21 June 2024
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 135 (1) , 60-75
3D Imaging Reveals Complex Microvascular Remodeling in the Right Ventricle in Pulmonary Hypertension
BACKGROUND: Pathogenic concepts of right ventricular (RV) failure in pulmonary arterial hypertension focus on a critical loss of microvasculature. However, the methods underpinning prior studies did not take into account the 3-dimensional (3D) aspects of cardiac tissue, making accurate quantification difficult. We applied deep-tissue imaging to the pressure-overloaded RV to uncover the 3D properties of the microvascular network and determine whether deficient microvascular adaptation contributes to RV failure. METHODS: Heart sections measuring 250-µm-thick were obtained from mice after pulmonary artery banding (PAB) or debanding PAB surgery and properties of the RV microvascular network were assessed using 3D imaging and quantification. Human heart tissues harvested at the time of transplantation from pulmonary arterial hypertension cases were compared with tissues from control cases with normal RV function. RESULTS: Longitudinal 3D assessment of PAB mouse hearts uncovered complex microvascular remodeling characterized by tortuous, shorter, thicker, highly branched vessels, and overall preserved microvascular density. This remodeling process was reversible in debanding PAB mice in which the RV function recovers over time. The remodeled microvasculature tightly wrapped around the hypertrophied cardiomyocytes to maintain a stable contact surface to cardiomyocytes as an adaptation to RV pressure overload, even in end-stage RV failure. However, microvasculature-cardiomyocyte contact was impaired in areas with interstitial fibrosis where cardiomyocytes displayed signs of hypoxia. Similar to PAB animals, microvascular density in the RV was preserved in patients with end-stage pulmonary arterial hypertension, and microvascular architectural changes appeared to vary by etiology, with patients with pulmonary veno-occlusive disease displaying a lack of microvascular complexity with uniformly short segments. CONCLUSIONS: 3D deep tissue imaging of the failing RV in PAB mice, pulmonary hypertension rats, and patients with pulmonary arterial hypertension reveals complex microvascular changes to preserve the microvascular density and maintain a stable microvascular-cardiomyocyte contact. Our studies provide a novel framework to understand microvascular adaptation in the pressure-overloaded RV that focuses on cell-cell interaction and goes beyond the concept of capillary rarefaction.
- 7 June 2024
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 39 (2) , 373-384
Cardiorenal Syndrome in Right Heart Failure Due to Pulmonary Arterial Hypertension—The Right Ventricle as a Therapeutic Target to Improve Renal Function
Cardiorenal syndrome (CRS) due to right ventricular (RV) failure is a disease entity emerging as a key indicator of morbidity and mortality. The multifactorial aspects of CRS and the left-right ventricular interdependence complicate the link between RV failure and renal function. RV failure has a direct pathophysiological link to renal dysfunction by leading to systemic venous congestion in certain circumstances and low cardiac output in other situations, both leading to impaired renal perfusion. Indeed, renal dysfunction is known to be an independent predictor of mortality in patients with pulmonary arterial hypertension (PAH) and RV failure. Thus, it is important to further understand the interaction between the RV and renal function. RV adaptation is critical to long-term survival in patients with PAH. The RV is also known for its remarkable capacity to recover once the aggravating factor is addressed or mitigated. However, less is known about the renal potential for recovery following the resolution of chronic RV failure. In this review, we provide an overview of the intricate relationship between RV dysfunction and the subsequent development of CRS, with a particular emphasis on PAH. Additionally, we summarize potential RV-targeted therapies and their potential beneficial impact on renal function.
- 7 June 2024
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 39 (2) , 373-384
Cardiorenal Syndrome in Right Heart Failure Due to Pulmonary Arterial Hypertension—The Right Ventricle as a Therapeutic Target to Improve Renal Function
Cardiorenal syndrome (CRS) due to right ventricular (RV) failure is a disease entity emerging as a key indicator of morbidity and mortality. The multifactorial aspects of CRS and the left-right ventricular interdependence complicate the link between RV failure and renal function. RV failure has a direct pathophysiological link to renal dysfunction by leading to systemic venous congestion in certain circumstances and low cardiac output in other situations, both leading to impaired renal perfusion. Indeed, renal dysfunction is known to be an independent predictor of mortality in patients with pulmonary arterial hypertension (PAH) and RV failure. Thus, it is important to further understand the interaction between the RV and renal function. RV adaptation is critical to long-term survival in patients with PAH. The RV is also known for its remarkable capacity to recover once the aggravating factor is addressed or mitigated. However, less is known about the renal potential for recovery following the resolution of chronic RV failure. In this review, we provide an overview of the intricate relationship between RV dysfunction and the subsequent development of CRS, with a particular emphasis on PAH. Additionally, we summarize potential RV-targeted therapies and their potential beneficial impact on renal function.
- Open Access
- 28 March 2024
- Published by Elsevier in JACC: Basic To Translational Science
- Vol. 9 (3) , 319-321
Mitochondrial Targeted Therapies to Prevent Maternal Diabetes–Induced Congenital Heart Defects
- 28 March 2024
- Published by Elsevier in JACC: Basic To Translational Science
- Vol. 9 (3) , 319-321
Open AccessMitochondrial Targeted Therapies to Prevent Maternal Diabetes–Induced Congenital Heart Defects
- Top Cited PapersOpen Access
Effect of Sodium-Glucose Cotransporter 2 Inhibitors in Adults With Congenital Heart Disease
Top Cited PapersOpen AccessEffect of Sodium-Glucose Cotransporter 2 Inhibitors in Adults With Congenital Heart Disease
- Open Access
- 6 February 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (3) , e029427
MicroRNA‐34a‐Dependent Attenuation of Angiogenesis in Right Ventricular Failure
Background: The right ventricle (RV) is at risk in patients with complex congenital heart disease involving right‐sided obstructive lesions. We have shown that capillary rarefaction occurs early in the pressure‐loaded RV. Here we test the hypothesis that microRNA (miR)‐34a, which is induced in RV hypertrophy and RV failure (RVF), blocks the hypoxia‐inducible factor‐1α‐vascular endothelial growth factor (VEGF) axis, leading to the attenuated angiogenic response and increased susceptibility to RV failure. Methods and Results: Mice underwent pulmonary artery banding to induce RV hypertrophy and RVF. Capillary rarefaction occurred immediately. Although hypoxia‐inducible factor‐1α expression increased (0.12±0.01 versus 0.22±0.03, P =0.05), VEGF expression decreased (0.61±0.03 versus 0.22±0.05, P =0.01). miR‐34a expression was most upregulated in fibroblasts (4‐fold), but also in cardiomyocytes and endothelial cells (2‐fold). Overexpression of miR‐34a in endothelial cells increased cell senescence (10±3% versus 22±2%, P <0.05) by suppressing sirtulin 1 expression, and decreased tube formation by 50% via suppression of hypoxia‐inducible factor‐1α, VEGF A, VEGF B, and VEGF receptor 2. miR‐34a was induced by stretch, transforming growth factor‐β1, adrenergic stimulation, and hypoxia in cardiac fibroblasts and cardiomyocytes. In mice with RVF, locked nucleic acid‐antimiR‐34a improved RV shortening fraction and survival half‐time and restored capillarity and VEGF expression. In children with congenital heart disease–related RVF, RV capillarity was decreased and miR‐34a increased 5‐fold. Conclusions: In summary, miR‐34a from fibroblasts, cardiomyocytes, and endothelial cells mediates capillary rarefaction by suppressing the hypoxia‐inducible factor‐1α‐VEGF axis in RV hypertrophy/RVF, raising the potential for anti‐miR‐34a therapeutics in patients with at‐risk RVs.
- 6 February 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (3) , e029427
Open AccessMicroRNA‐34a‐Dependent Attenuation of Angiogenesis in Right Ventricular Failure
Background: The right ventricle (RV) is at risk in patients with complex congenital heart disease involving right‐sided obstructive lesions. We have shown that capillary rarefaction occurs early in the pressure‐loaded RV. Here we test the hypothesis that microRNA (miR)‐34a, which is induced in RV hypertrophy and RV failure (RVF), blocks the hypoxia‐inducible factor‐1α‐vascular endothelial growth factor (VEGF) axis, leading to the attenuated angiogenic response and increased susceptibility to RV failure. Methods and Results: Mice underwent pulmonary artery banding to induce RV hypertrophy and RVF. Capillary rarefaction occurred immediately. Although hypoxia‐inducible factor‐1α expression increased (0.12±0.01 versus 0.22±0.03, P =0.05), VEGF expression decreased (0.61±0.03 versus 0.22±0.05, P =0.01). miR‐34a expression was most upregulated in fibroblasts (4‐fold), but also in cardiomyocytes and endothelial cells (2‐fold). Overexpression of miR‐34a in endothelial cells increased cell senescence (10±3% versus 22±2%, P <0.05) by suppressing sirtulin 1 expression, and decreased tube formation by 50% via suppression of hypoxia‐inducible factor‐1α, VEGF A, VEGF B, and VEGF receptor 2. miR‐34a was induced by stretch, transforming growth factor‐β1, adrenergic stimulation, and hypoxia in cardiac fibroblasts and cardiomyocytes. In mice with RVF, locked nucleic acid‐antimiR‐34a improved RV shortening fraction and survival half‐time and restored capillarity and VEGF expression. In children with congenital heart disease–related RVF, RV capillarity was decreased and miR‐34a increased 5‐fold. Conclusions: In summary, miR‐34a from fibroblasts, cardiomyocytes, and endothelial cells mediates capillary rarefaction by suppressing the hypoxia‐inducible factor‐1α‐VEGF axis in RV hypertrophy/RVF, raising the potential for anti‐miR‐34a therapeutics in patients with at‐risk RVs.